Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease
Open Access
- 7 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuroinflammation
- Vol. 17 (1), 1-13
- https://doi.org/10.1186/s12974-020-01934-x
Abstract
The type 1 interferon (IFN) response is part of the innate immune response and best known for its role in viral and bacterial infection. However, this pathway is also induced in sterile inflammation such as that which occurs in a number of neurodegenerative diseases, including neuronopathic Gaucher disease (nGD), a lysosomal storage disorder (LSD) caused by mutations in GBA. Mice were injected with conduritol B-epoxide, an irreversible inhibitor of acid beta-glucosidase, the enzyme defective in nGD. MyTrMaSt null mice, where four adaptors of pathogen recognition receptors (PRRs) are deficient, were used to determine the role of the IFN pathway in nGD pathology. Activation of inflammatory and other pathways was analyzed by a variety of methods including RNAseq. Elevation in the expression of PRRs associated with the IFN response was observed in CBE-injected mice. Ablation of upstream pathways leading to IFN production had no therapeutic benefit on the lifespan of nGD mice but attenuated neuroinflammation. Primary and secondary pathological pathways (i.e., those associated or not with mouse survival) were distinguished, and a set of ~210 genes including those related to sphingolipid, cholesterol, and lipoprotein metabolism, along with a number of inflammatory pathways related to chemokines, TNF, TGF, complement, IL6, and damage-associated microglia were classified as primary pathological pathways, along with some lysosomal and neuronal genes. Although IFN signaling is the top elevated pathway in nGD, we demonstrate that this pathway is not related to mouse viability and is consequently defined as a secondary pathology pathway. By elimination, we defined a number of critical pathways that are directly related to brain pathology in nGD, which in addition to its usefulness in understanding pathophysiological mechanisms, may also pave the way for the development of novel therapeutic paradigms by targeting such pathways.Funding Information
- Children's Gaucher Research Fund
This publication has 59 references indexed in Scilit:
- Matrix Metalloproteinases, New Insights into the Understanding of Neurodegenerative DisordersBiomolecules & Therapeutics, 2012
- Fatty Acids Modulate Toll-like Receptor 4 Activation through Regulation of Receptor Dimerization and Recruitment into Lipid Rafts in a Reactive Oxygen Species-dependent MannerOnline Journal of Public Health Informatics, 2009
- Activation of innate immune antiviral responses by Nod2Nature Immunology, 2009
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease InhibitorPLOS ONE, 2008
- BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagramsBMC Genomics, 2008
- Murine models of acute neuronopathic Gaucher diseaseProceedings of the National Academy of Sciences of the United States of America, 2007
- Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicityFEBS Letters, 2007
- The family of five: TIR-domain-containing adaptors in Toll-like receptor signallingNature Reviews Immunology, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001